![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, November 08, 2020 9:18:03 PM
5:47 pm ET November 7, 2020 (Benzinga)
Oregon has become the first state in US history to set up a program that regulates psilocybin, the active psychedelic ingredient in “magic mushrooms.”
Measure 109 was approved by 55.8% of voters in a ballot vote on Election Day.
The measure creates a state-licensed psilocybin-assisted therapy system. Patients over the age of 21 will be allowed to buy, possess and use psilocybin under the supervision of trained facilitators, while manufacture, delivery and administration of the drug will be allowed at supervised, licensed facilities.
“Now there is a new form of hope for all Oregonians and those willing to travel to Oregon rather than places like Jamaica where psychedelic retreats are already legal,” said Mike Arnold, Founder and President of Silo Wellness, an Oregon-based company with retreat operations in Jamaica.
Field Trip Health (CSE: FTRP) (OTC: FTRPF) also announced intentions to establish therapy clinics in the Beaver State, stating that it is “in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies.”
The approved legislation sets up a two-year period to develop the program and put it into action.
Oregonians also approved separate legislation, called Measure 110, which decriminalizes possession and use of all scheduled drugs including heroin, cocaine and methamphetamine.
Washington DC Decriminalizes Psychedelic Plants And Fungi
Voters in the District of Columbia have approved an initiative that aims to effectively decriminalize the use of several psychedelic substances.
Initiative 81 makes non-commercial possession, distribution, purchase and cultivation of psychedelic and hallucinogenic plants and fungi a lowest law enforcement priority for the Metropolitan Police Department.
The measure includes a non-binding call for the D.C. attorney general and U.S. attorney for DC to "cease prosecution of criminal charges involving these substances,” which are also referred to as “entheogens.”
The ballot initiative was approved by 76% of voters.
Initiative 81 does not change penalties regarding these plants, nor does it allow commercial sales.
The measure is similar to those taken by other jurisdictions like Denver; Oakland and Santa Cruz in California, and Ann Arbor, MIch., in recent years.
Cybin And Entheon Biomedical To Go Public Next Week
Two psychedelics companies announced plans to begin public listings of their stock, starting next week.
Cybin, a Toronto-based psychedelics research company, announced on Thursday it has completed a reverse take-over with Clarmin Explorations Inc.
The company’s stock will be available on the NEO exchange on November 10 under the symbol CYBN.
Last week, the company announced the closing of a private offering for CA$45 million ($34.2 million).
Cybin is currently working towards a Phase 2 clinical trial to study psilocybin use for major depressive disorder. The trial will include 120 patients taking four doses of a sublingual film containing psilocybin over a four-month period.
Entheon Biomedical also announced a go-public date on Thursday.
The company closed its reverse acquisition with MPV Exploration Inc. and announced that its stock will be available on the Canadian Securities Exchange on November 12 under the symbol ENBI.
Entheon is a psychedelic-drug development company focused on developing DMT-based medicines for substance abuse disorder. DMT, or N,N-Dimethyltryptamine, is a short-acting psychedelic molecule present in ayahuasca, an hallucinogenic beverage traditionally used by indigenous people of the Amazon basin.
MindMed Completes LSD Study
MindMed (NEO: MMED) (OTCQB: MMEDF) completed a phase 1 study on LSD. The study examined different doses of the drug in healthy individuals to understand how its effect varies between doses.
“Maximal good drug effects were reached at a 100ug dose. However, an experiential dose of 200ug LSD was shown to induce greater ego dissolution than a lesser 100ug dose,” said a press release.
Ego dissolution is believed to be one of the key elements behind the therapeutic potential of psychedelic-assisted therapy.
The company now expects to move to a Phase 2b clinical trial to assess the efficacy of LSD-assisted therapy for anxiety disorders.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Recent MNMD News
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • Business Wire • 06/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:10 PM
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:10 PM
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM